Medigene Ag

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Pieris Pharmaceuticals Gmbh

Fougera Pharmaceuticals Inc.

Ulrich Moebius

Yunik Chang

Robert Lathrop

Irene Gander-Meisterernst

Erwin Böhm

Regina Greger

Johanna Holldack

Yi Li

Gerhard Moldenhauer

Peter Altevogt

Daniela Kelm

Achim Krueger

Sandra Luettgau

Susanne Sebens

Heiner Schaefer

Christine Rothe

Michael Hallek

Marlon Hinner

Rachida Siham Bel Aiba

Shane Olwill

Frank Breitling

Anne Girod

Martin Ried

Erwin Bohm

Corinna Schlosser

Frank Brietling

Silke Baerreiter

Silke Wolterink

Thomas Jean Jaquin

Christof Körner

The disclosure provides a fusion polypeptide specific for both CD137 and HER2/neu, which fusion polypeptide can be useful for directing CD137 clustering and activation to HER2/neu-positive tumor cells. Such fusion polypeptide can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as a variety of tumors. The present disclosure also concerns methods of making the fusion polypeptide described herein as well as compositions comprising such fusion polypeptide. The present disclosure further relates to nucleic acid molecules encoding such fusion polypeptide and to methods for generation of such fusion polypeptide and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such fusion polypeptide as well as compositions comprising one or more of such fusion polypeptides.

Anti-cancer fusion polypeptide

The invention relates to a medicament containing a compound of general formula (I), where R=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C-Calkyl, alkylene or alkinyl group, preferably a C-Calkyl, alkylene or alkinyl group, particularly a C-Calkyl, alkylene or alkinyl group, most preferably a Calkyl group, R=independently, a straight or branched C-Calkyl, alkylene or alkinyl group, preferably a C-Calkyl, alkylene or alkinyl group, in particular a C-Calkyl, alkylene or alkinyl group, most preferably a Calkyl group, a &#x2014;[CH&#x2014;(CH)m-O]H group with n=1 to 10, preferably n=1 to 5, to m=1 to 5, preferably m=1 to 3, a &#x2014;CH&#x2014;[CH&#x2014;(OH)][CH&#x2014;R]&#x2014; group, where R=independently H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumor diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof.

Medicament for the treatment of viral skin and tumour diseases

The invention relates to a medicament containing a compound of general formula (I), where R=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C-Calkyl, alkylene or alkinyl group, preferably a C-Calkyl, alkylene or alkinyl group, particularly a C-Calkyl, alkylene or alkinyl group, most preferably a Calkyl group, R=independently, a straight or branched C-Calkyl, alkylene or alkinyl group, preferably a C-Calkyl, alkylene or alkinyl group, in particular a C-Calkyl, alkylene or alkinyl group, most preferably a Calkyl group, a &#x2014;[CH&#x2014;(CH)m-O]H group with n=1 to 10, preferably n=1 to 5, to m=1 to 5, preferably m=1 to 3, a &#x2014;CH&#x2014;[CH&#x2014;(OH)][CH&#x2014;R]- group, where R=independently H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumor diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof.

The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.

Treatment of tumors using specific anti-L1 antibody

The invention relates to a medicament containing a compound of general formula (1), where R=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C-Calkyl, alkylene or alkynyl group, preferably a C-Calkyl, alkylene or alkynyl group, particularly a C-Calkyl, alkylene or alkynyl group, most preferably a Calkyl group, R2=independently, a straight or branched C-Calkyl, alkylene or alkynyl group, preferably a C-Calkyl, alkylene or alkynyl group, in particular a C-Calkyl, alkylene or alkynyl group, most preferably a Calkyl group, a &#x2014;[CH&#x2014;(CH)&#x2014;O]H group with n=1 to 10, preferably n=1 to 5, m=1 to 5, preferably m=1 to 3, a &#x2014;CH&#x2014;[CH&#x2014;(OH)][CH&#x2014;(R)]&#x2014; group, where R=independent H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumor diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof. 

The invention relates to a scleroprotein of an adeno-associated virus which contains at least one mutation. Said mutation causes the chromatographic properties to be modified. The invention also relates to the production of said scleroprotein and the use thereof.

Scleroprotein of an adeno-associated virus with modified chromatographic properties, the production thereof and use of the same

Growing community of inventors

Gauting-Unterbrunn, Germany

Ulrich Moebius